LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow outflow grows to $93.83M
Q1 FY2026 financing cash flow was $93.83M, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $396.39M. Over 3 fiscal years it compounded at +136.2% a year.
Context
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly financing cash flow holds near $93.83M or moves back toward the trailing-twelve-month quarterly average of $99.1M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 302.56M USD
- Year-over-year change
- +689.7%
- 3-year CAGR
- +136.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 302.56M | +689.7% |
| FY2024 | 2024-12-31 | 38.32M | +13.8% |
| FY2023 | 2023-12-31 | 33.68M | +46.7% |
| FY2022 | 2022-12-31 | 22.96M | — |
Financing Cash Flow vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's LTM Mar 2026 financing cash flow of $396.39M is the 5th largest of the 10 companies compared; the peer median is $271.31M.
- Over three fiscal years its annual growth of +136.2% compares with a peer median of +65.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.32B | — | — | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $1.03B | +3969.6% | +65.4% | — |
| LTM Mar 2026 | $463.02M | +23881.0% | +141.9% | — | |
| LTM Jun 2026 | $425.38M | +1810.7% | -15.2% | 11803.1% | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $396.39M | — | +136.2% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $271.31M | +71.7% | +89.7% | 1356.6% |
| LTM Mar 2026 | $165.89M | +1517.0% | +11.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $87.96M | +345.2% | -12.7% | — |
| LTM Jun 2026 | $51.05M | +154.8% | +82.6% | 4.5% | |
| LTM Mar 2026 | $2.23M | -101.6% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $271.31M | +931.1% | +65.4% | 1356.6% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (14.35M) | (6.28M) | (63.1M) | (25.21M) |
| Depreciation & Amortization | 2K | 4K | 91K | 321K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 431K | 295K | 3.16M | 0 |
| Change in Working Capital | 86K | (1.31M) | 3.31M | (13.65M) |
| Accounts Receivables | 0 | (154K) | 114K | (268K) |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | (910K) |
| Other Working Capital | 86K | (1.16M) | 3.2M | (12.47M) |
| Other Non-Cash Items | 11.1M | (4.81M) | 3.49M | 3.33M |
| Operating Cash Flow | (2.73M) | (12.09M) | (53.05M) | (35.21M) |
| Capital Expenditures | 0 | (25K) | (769K) | (52K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (33.99M) | (29.75M) | (44.84M) |
| Sales of Investments | 123K | 6M | 53.75M | 5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 123K | (28.01M) | 23.23M | (39.89M) |
| Debt Repayment | 25.01M | 725K | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 302.56M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.95M) | (2.05M) | (1.69M) | 0 |
| Financing Cash Flow | 22.96M | 33.68M | 38.32M | 302.56M |
| Effect of Forex Changes | 0 | 0 | 0 | (272K) |
| Net Change in Cash | 20.36M | (6.43M) | 8.5M | 227.2M |
| Free Cash Flow | (2.73M) | (12.12M) | (53.82M) | (35.26M) |
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.